Bionano Genomics, Inc. filings document the formal disclosures of a genome-analysis company commercializing optical genome mapping solutions, diagnostic testing services, genome-analysis software and nucleic acid extraction and purification technologies. Form 8-K reports record financial results, preliminary results, material agreements, securities offerings and executive leadership changes, while registration statements describe offered common stock, pre-funded warrants and warrant securities.
Proxy materials cover board elections, executive compensation, equity-award matters, shareholder voting and governance practices. The filing record also documents capital-structure changes, Nasdaq-listed common stock disclosures, risk factors and exhibits tied to Bionano’s OGM, VIA software, Ionic system and Bionano Laboratories operations.
Bionano Genomics, Inc. (BNGO) seeks to register up to 1,332,632 shares of common stock issuable upon exercise of outstanding warrants; the shares may not be sold until the registration statement is effective. The registered amount comprises 661,377 shares under 2025 Purchase Warrants at $15.120 per share, 164,684 shares under Series C Warrants at $18.234 per share, 145,560 shares under 2024 Purchase Warrants at $61.20 per share, and 361,011 shares under 2023 Purchase Warrants at $191.13 per share.
Bionano estimates approximately $90 million in proceeds if all warrants are exercised; holders may exercise some or none, and the company receives no proceeds from later sales of the underlying shares. It intends to use net proceeds, together with existing cash and cash equivalents and available-for-sale securities, for general corporate purposes, including working capital, research and development, and capital expenditures. Full exercise would result in 15,309,589 shares outstanding, compared with 13,976,957 shares outstanding as of October 23, 2026. The company identifies its ability to continue as a going concern within 12 months of filing its Quarterly Report for the quarter ended June 30, 2026, requiring cost management and significant additional financing.
Bionano Genomics, Inc. (BNGO) has a reported beneficial ownership position of 1,165,000 common shares, equal to 9.9% of the class, attributed to AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman. Hirschman is identified as managing member of AIGH Capital Management LLC and president of AIGH Investment Partners LLC. The reporting persons report sole voting and dispositive power over 1,165,000 shares. The reported amount excludes 2,374,000 shares issuable upon warrants.
Bionano Genomics, Inc. (BNGO) released an investor presentation alongside a conference appearance outlining recent operating progress and forward-looking expectations. Management highlights a multi‑year financial transformation from FY2023–FY2025, including a 71% reduction in non‑GAAP operating expenses from $126 million to $36 million, a 25‑point improvement in adjusted core gross margin from 22% to 47%, and an 84% reduction in adjusted EBITDA loss from $(121.1) million to $(19.2) million.
For Q2 2026, core revenue was $8 million, up 21% year over year and above prior guidance, with record flow cell sales and 53% adjusted gross margin. Full‑year FY2026 revenue guidance is $31–33 million, and management presents an outlook for total revenue of $50–54 million in FY2027 and $101–108 million in FY2029 with improving GAAP gross margins and an expected transition to positive adjusted EBITDA by FY2028–FY2029. The presentation also emphasizes optical genome mapping (OGM) adoption, including two American Medical Association Category I CPT codes and a MolDX Local Coverage Determination for OGM in hematologic malignancies, while reiterating risks such as the need for additional financing and the company’s disclosed going‑concern uncertainty.
Bionano Genomics, Inc. (BNGO) reported that Interim Chief Executive and director Albert Luderer purchased 4,000 shares of common stock on September 4, 2026 in an open market or private transaction. The shares are held indirectly through a Traditional IRA, bringing his indirect holdings in that account to 8,000 shares.
Bionano Genomics, Inc. (BNGO) reported that interim Chief Executive and director Albert Luderer indirectly purchased 4,000 shares of Common Stock on 2026-08-21 in an open-market or private transaction at $1.215 per share. The shares are held indirectly through a Traditional IRA, and this filing does not indicate use of a Rule 10b5-1 trading plan.
CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of 1,307,135 shares of Bionano Genomics, Inc. common stock, representing 9.9% of the class. The position consists entirely of shares issuable upon exercise of warrants.
The warrants are subject to ownership caps: a portion cannot be exercised if it would cause aggregated beneficial ownership to exceed 4.99%, and the remainder cannot be exercised above 9.99%. Bionano Genomics reported 11,777,300 shares outstanding as of June 30, 2026, which is used to calculate the ownership percentage. Heights Capital Management acts as investment manager to CVI and may be deemed to share voting and dispositive power, while each reporting person disclaims beneficial ownership beyond its pecuniary interest.
Bionano Genomics, Inc. reported higher revenue but continuing losses for the quarter and six months ended June 30, 2026. Total revenue grew to $8.2M for the quarter (up from $6.7M) and $14.9M for the six months (up from $13.2M), driven mainly by instruments and consumables. Quarterly instrument revenue rose 46% to $2.0M and consumables 31% to $4.3M, supported by an installed base of 397 OGM systems and 9,219 flowcells sold in the quarter.
Gross margin was 53% for the quarter, similar to the prior year period. Operating expenses were essentially flat year over year for the six months, but the company remains unprofitable, with a net loss of $7.4M in the quarter and $15.7M year-to-date, widening versus 2025. Accumulated deficit reached $735.3M.
Liquidity is constrained: as of June 30, 2026, Bionano had $3.7M in cash and cash equivalents, $6.2M in short-term investments and $14.8M of working capital. Management used $10.4M of cash in operating activities in the first half and states there is substantial doubt about the company’s ability to continue as a going concern without additional capital. The company fully redeemed its $10.3M JGB convertible debentures at maturity and raised about $1.3M of equity under a $75M at-the-market program.
Bionano Genomics, Inc. reported second quarter 2026 results with continued growth in its optical genome mapping business. For the three months ended June 30, 2026, total revenue was $8.2 million, up 21% from $6.7 million a year earlier, driven largely by consumables and clinical adoption. Consumables revenue reached $4.3 million, up 31%, and 9,219 nanochannel array flow cells were sold, a 27% increase over 7,233 in 2025. GAAP gross margin was 53% versus 52% a year ago, while operating expenses rose 2% to $11.5 million; total adjusted operating expense declined 2% to $8.7 million. The company recorded a GAAP net loss of $7.4 million for the quarter and $15.7 million for the first half of 2026. Management highlighted the completed full retirement of all outstanding Senior Secured Convertible Debentures, eliminating secured debt and related liens, and cited strong growth in OGM-related publications and conference activity. Guidance calls for Q3 2026 revenue of $8.2–$8.6 million and full-year 2026 revenue of $31–$33 million.
Bionano Genomics, Inc. reported that Principal Accounting Officer Mark Adamchak received a grant of 5,000 stock options to buy common stock at an exercise price of $1.12 per share, vesting 50% on each of the first and second anniversaries of the vesting commencement date and expiring on August 2, 2036. This Form 4 replaces an erroneously filed initial Form 3.
Bionano Genomics, Inc. reported that its General Counsel, Jonathan V. Dixon, received a grant of stock options for 15,000 shares of common stock on 2026-08-03. The options have an exercise price of $1.12 per share and expire on 2036-08-02. The award vests 50% on each of the first and second anniversaries of the vesting commencement date, subject to Continuous Service under the company’s 2018 Plan. Following this grant, Dixon holds options covering 15,000 shares. The company also states that this filing replaces an erroneously filed initial Form 3 dated August 5, 2026.